F m Investments LLC Purchases 23,282 Shares of Mirum Pharmaceuticals, Inc. $MIRM

F m Investments LLC raised its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 78.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 53,088 shares of the company’s stock after purchasing an additional 23,282 shares during the quarter. F m Investments LLC’s holdings in Mirum Pharmaceuticals were worth $4,193,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. MCF Advisors LLC grew its stake in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares during the period. Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $33,000. Comerica Bank grew its stake in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. Quarry LP bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $41,000. Finally, CWM LLC grew its stake in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the period.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 4,732 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $435,249.36. Following the completion of the transaction, the senior vice president directly owned 8,429 shares in the company, valued at $775,299.42. This represents a 35.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Christopher Peetz sold 40,985 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $3,769,800.30. Following the completion of the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at $17,872,541.82. The trade was a 17.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 76,806 shares of company stock worth $7,064,616 over the last ninety days. 14.36% of the stock is owned by company insiders.

Mirum Pharmaceuticals Trading Up 4.1%

Shares of NASDAQ:MIRM opened at $107.16 on Friday. The stock has a 50 day moving average of $93.79 and a 200 day moving average of $86.06. The company has a market cap of $6.53 billion, a PE ratio of -7.87 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 12-month low of $42.89 and a 12-month high of $112.00. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 10.84%. The business had revenue of $159.88 million for the quarter, compared to the consensus estimate of $148.21 million. During the same period last year, the business posted ($0.30) EPS. The firm’s revenue for the quarter was up 43.3% compared to the same quarter last year. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -8.25 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on MIRM shares. Raymond James Financial reiterated a “strong-buy” rating and set a $165.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday. Leerink Partners cut their price objective on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Evercore reiterated an “outperform” rating and set a $138.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Morgan Stanley boosted their price objective on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the company an “overweight” rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $136.42.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum jumped after investors reacted to positive Volixibat Phase 2b data in primary sclerosing cholangitis (PSC), which supports the company’s pipeline and has likely improved confidence in future growth. Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss – Has The Bull Case Changed?
• Positive Sentiment: HC Wainwright raised its FY2027 earnings estimate for Mirum Pharmaceuticals to $0.70 per share from $0.63, suggesting stronger longer-term profitability expectations.
• Positive Sentiment: The firm also lifted its Q4 2026 EPS estimate to a smaller loss of $(0.06) from $(0.09), which points to improving near-term earnings momentum.
• Neutral Sentiment: HC Wainwright now expects Mirum to turn profitable in later periods, including $0.02 EPS in Q2 2027, $0.26 in Q3 2027, and $0.49 in Q4 2027, reinforcing a more constructive long-term view.
• Negative Sentiment: Despite the improved outlook, the analyst still sees losses through most of 2026, including a larger Q2 2026 loss estimate of $(0.58) and a Q3 2026 loss estimate of $(1.06), highlighting that profitability remains some time away.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.